Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sinusitis
Special Issues
Frontiers in Chronic Rhinosinusitis with Nasal Polyposis
share announcement

Frontiers in Chronic Rhinosinusitis with Nasal Polyposis

A special issue of Sinusitis (ISSN 2673-351X).

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 4636

Special Issue Editors

Dr. Antonella Loperfido

E-Mail Website
Guest Editor
Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Interests: chronic rhinosinusitis
Dr. Rodolfo Francesco Mastrapasqua

E-Mail Website
Co-Guest Editor
Rivoli Hospital, ASL TO3, Turin, Italy
Interests: chronic rhinosinusitis with nasal polyposis

Special Issue Information

Dear Colleagues,

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory condition of the sinonasal mucosa. Recent discoveries have confirmed the paramount role of endotyping, thus revealing the crucial role of cytokines of type 2 inflammation in the pathogenesis of the most severe forms of CRSwNP.

The standard therapeutic approach to CRSwNP typically consists of the use of local or systemic corticosteroids and/or sinonasal endoscopic surgery. However, patients with severe and uncontrolled CRSwNP may need high systemic corticosteroid use and/or multiple surgical approaches.

The role of new biological drugs targeting type 2 inflammation cytokines is emerging and may represent an additional therapeutic option in selected patients.

The purpose of this Special Issue is to investigate the latest evidence regarding the use of biological drugs in CRSwNP, highlighting the biological, epidemiological, clinical, and socioeconomic aspects, with a special focus on the impact of these drugs on the quality of life of patients.

Dr. Antonella Loperfido
Dr. Rodolfo Francesco Mastrapasqua
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sinusitis is an international peer-reviewed open access semiannually journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic rhinosinusitis with nasal polyposis
  • chronic inflammatory
  • biological drugs
  • the quality of life of patients

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

11 pages, 2000 KiB  
Review
Chronic Rhinosinusitis with Nasal Polyposis in People with Cystic Fibrosis
by Jessa E. Miller, Jennifer L. Taylor-Cousar and Daniel M. Beswick
Sinusitis 2023, 7(2), 27-37; https://doi.org/10.3390/sinusitis7020004 - 31 Oct 2023
Viewed by 2083
Abstract
Cystic fibrosis (CF) is an autosomal recessive disorder that results in deranged ion transport and affects multiple organ systems, including the upper and lower respiratory tracts. People with CF (PwCF) often develop chronic rhinosinusitis (CRS) with or without nasal polyposis. CRS can significantly [...] Read more.
Cystic fibrosis (CF) is an autosomal recessive disorder that results in deranged ion transport and affects multiple organ systems, including the upper and lower respiratory tracts. People with CF (PwCF) often develop chronic rhinosinusitis (CRS) with or without nasal polyposis. CRS can significantly decrease quality of life for PwCF and can lead to more frequent pulmonary exacerbations. The management of CRS in PwCF is different from that in individuals without CF. Novel therapies have emerged in the last several years that have drastically altered the progression of both pulmonary and sinonasal disease in people with CF. It is critical for providers who manage CF-related CRS to understand the unique characteristics and challenges that coincide with this disease process. This review article aims to provide readers with an overview of the pathophysiology of CF and to summarize best practice strategies for the management of CF-related CRS. Full article
(This article belongs to the Special Issue Frontiers in Chronic Rhinosinusitis with Nasal Polyposis)
►▼ Show Figures

Figure 1

15 pages, 403 KiB  
Review
Central Compartment Atopic Disease as a Pathophysiologically Distinct Subtype of Chronic Rhinosinusitis: A Scoping Review
by Camron Davies, Franklin Wu, Emily Y. Huang, Masayoshi Takashima, Nicholas R. Rowan and Omar G. Ahmed
Sinusitis 2023, 7(2), 12-26; https://doi.org/10.3390/sinusitis7020003 - 21 Sep 2023
Viewed by 2021
Abstract
Central compartment atopic disease (CCAD) is a distinct phenotype within chronic rhinosinusitis with nasal polyps (CRSwNP) with a pathophysiology that bridges the gap between allergy and CRSwNP, an association that was previously ambiguous. Understanding this endotype and its link to allergic disease is [...] Read more.
Central compartment atopic disease (CCAD) is a distinct phenotype within chronic rhinosinusitis with nasal polyps (CRSwNP) with a pathophysiology that bridges the gap between allergy and CRSwNP, an association that was previously ambiguous. Understanding this endotype and its link to allergic disease is crucial for improved CCAD management. Using a systematic search and an independent dual-reviewer evaluation and data extraction process, this scoping review examines the clinical features, management options, and treatment outcomes of CCAD. Central compartment (CC) polypoid changes of the MT predominantly correlate with allergic rhinitis, increased septal inflammation, oblique MT orientation, and decreased nasal cavity opacification and Lund–Mackay scores compared to other CRSwNP subtypes. CCAD patients also exhibit higher rates of asthma, allergen sensitization, and hyposmia or anosmia. Surgical outcomes, including revision rate and SNOT-22 improvement, are favorable in CCAD as well. In conclusion, CCAD primarily affects atopic individuals and is managed using endoscopic sinus surgery combined with treating the underlying allergy. Continued research is needed to further refine understanding and develop optimal treatment strategies of this emerging CRS subtype. Full article
(This article belongs to the Special Issue Frontiers in Chronic Rhinosinusitis with Nasal Polyposis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop